HLTH - ETF AI Analysis
Top Page
Tema Healthcare AI ETF (HLTH)
Rating:53Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered strong gains so far this year, showing positive momentum in its strategy.
Leading Healthcare Innovators in Top Holdings
Several of the largest positions, especially in genomics and biotech, have shown strong performance, helping drive the fund’s overall results.
Focused Exposure to Healthcare AI Theme
The fund’s heavy tilt toward healthcare and related technology gives investors targeted access to a growing, specialized area of the market.
Negative Factors
High Expense Ratio
The ETF charges relatively high fees, which can eat into long-term returns compared with lower-cost funds.
Concentrated Sector and Country Exposure
With most assets in U.S. healthcare stocks, investors face higher risk if this sector or region experiences a downturn.
Mixed Performance Among Top Holdings
A few of the largest positions have shown weak or lagging returns, which can offset gains from stronger-performing stocks.
HLTH Historical Chart
AUM11.15M
RegionGlobal
Expense Ratio0.75%
Beta0.26
IssuerTema
Inception DateJul 21, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,051
30 Day Avg. Volume10,497
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.02Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering33
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HLTH Summary
The Tema Healthcare AI ETF (HLTH) is a fund that focuses on companies using artificial intelligence to improve health care, rather than tracking a traditional market index. It holds a mix of drug makers, medical device companies, and digital health firms working on things like smarter diagnostics, genomics, and remote patient monitoring. Well-known names in the fund include Intuitive Surgical and Vertex Pharmaceuticals. An investor might choose HLTH for long-term growth and to tap into the trend of AI in medicine. However, because it is concentrated in health care and AI-related stocks, its price can be more volatile and may go up and down sharply.
How much will it cost me?HLTH has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 invested. This is higher than the average ETF cost because HLTH is actively managed and focuses on a specialized theme—healthcare companies using AI—rather than tracking a broad, low-cost index.
What would affect this ETF?This ETF could benefit if artificial intelligence continues to gain traction in global health care, boosting demand for tools from companies like 10x Genomics, Illumina, and Intuitive Surgical, and if health-care spending and innovation remain strong worldwide. On the downside, it is heavily focused on health-care and biotech names, so setbacks in drug development, tighter health-care regulations, or rising interest rates that hurt growth stocks could weigh on performance, and its global exposure means it can be affected by policy changes and economic slowdowns in multiple regions.
HLTH Top 10 Holdings
HLTH is leaning hard into genomics and precision medicine, with rising names like 10x Genomics, Twist Bioscience, and Natera acting as the main growth engines as investors warm to AI-driven lab tools and diagnostics. Illumina and Guardant Health add steady, large-cap ballast to the sequencing and liquid-biopsy theme, helping smooth out some of the bumps. On the flip side, Cytokinetics and Cogent Biosciences are lagging, dragging on returns as their biotech storylines remain more speculative. Overall, it’s a globally focused, AI-in-healthcare play with meaningful concentration in a handful of innovative U.S. names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| 10x Genomics | 6.95% | $774.27K | $10.51B | 603.14% | 60 Neutral | |
| Illumina | 5.78% | $643.96K | $42.00B | 196.37% | 71 Outperform | |
| Natera | 5.64% | $628.39K | $57.76B | 136.73% | 73 Outperform | |
| Twist Bioscience | 5.35% | $596.80K | $10.52B | 412.28% | 43 Neutral | |
| Intuitive Surgical | 5.33% | $594.04K | $149.78B | -1.31% | 78 Outperform | |
| Cytokinetics | 4.86% | $542.09K | $8.75B | 4.78% | 57 Neutral | |
| Cogent Biosciences | 4.55% | $506.82K | $5.38B | 90.53% | 37 Underperform | |
| Thermo Fisher | 4.41% | $491.59K | $243.30B | 25.38% | 72 Outperform | |
| Revolution Medicines | 4.40% | $490.05K | $40.67B | 293.37% | 52 Neutral | |
| Vertex Pharmaceuticals | 4.20% | $468.53K | $129.29B | 25.08% | 78 Outperform |
HLTH Technical Analysis
Neutral
―
Price Trends
28.47
Positive
Market Momentum
0.15
Positive
49.03
Neutral
16.60
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HLTH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 29.16, equal to the 50-day MA of 28.47, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 49.03 is Neutral, neither overbought nor oversold. The STOCH value of 16.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HLTH.
HLTH Peer Comparison
Comparison Results
Performance Comparison
HLTH
Tema Healthcare AI ETF
28.72
3.53
14.01%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents